Two studies have been published in Science Advances and a new platform capable of providing deep insights into T cell responses and TCR activation has been developed. The platform, referred to as T-FINDER, was designed by Dr. John M. Lindner and his research team at the BioMed X Institute in Heidelberg. The platform is capable of rapidly screening thousands of potential interactions between TCRs and antigens. Researchers also investigated immune responses of two diffuse midline glioma patients treated with a neoepitope peptide vaccine. The publication is a result of a collaboration between the BioMed X Institute, Universitätsmedizin Mannheim, the DKFZ, and the Helmholtz Institute for Translational Oncology.
Source link
New platform provides deep insights into T cell responses against novel cancer vaccine
